• Revenues up 110% to $968,878, loss down 24% to $6,759,135
• Successful prototype work with KOMA Biotech in South Korea for diagnostic applications
• Expanded five-year purchase agreement with Serum Institute of India, the world's largest vaccine manufacturer

In FY2025, AnteoTech Ltd (ASX: ADO) reported a 110% increase in revenues to $968,878 and a 24% decrease in loss to $6,759,135. The company's Advanced Battery Technologies division saw several milestones, including Ultranodeâ„¢ achieving 890 cycles at 80% capacity retention and 1,070 cycles at 70%, validating its potential for high-performance lithium-ion battery applications. AnteoTech also signed a binding term sheet with Black Diamond Structures (USA) to co-develop a next-generation AnteoXâ„¢ LiB additive for the North American market. In Life Sciences, the company expanded its five-year purchase agreement with Serum Institute of India, the world's largest vaccine manufacturer, and completed successful prototype work with KOMA Biotech in South Korea for diagnostic applications. The company also launched AnteoBind NXTâ„¢, offering improved performance and cost-effective solutions for diagnostic test development. AnteoTech underwent a strategic review in the second half of FY2025, resulting in organizational restructuring, strengthened business development and marketing capabilities, and greater definition of its product strategies and value propositions. The company is now positioned for growth, with a focus on securing sales globally, scaling production, and expanding strategic partnerships.

AnteoTech expects to secure sales globally across its product range in diverse end uses, scale production to meet sales growth, and secure and expand strategic partnerships to deliver sustainable value for shareholders.

Entering FY2026, AnteoTech is in a stronger, more focused position, with a future-ready strategy designed to capture growth opportunities. The company is well-prepared to deliver in FY2026 and beyond.